Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 14/20 | 0.63 |
| ▸ | PARP11 | Q9NR21 | 10/20 | 0.63 |
| ▸ | PARP1 | P09874 | 6/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 5/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25928045 | 0.90 | PARP10 (0.51) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL30549705 | 0.88 | PARP10 (0.68) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL1725257 | 0.87 | PARP10 (0.59) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL12459041 | 0.87 | PARP10 (0.71) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL1727568 | 0.86 | PARP10 (0.58) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL793156 | 0.83 | PARP10 (0.77) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL1726500 | 0.83 | PARP10 (0.55) | PARP10PARP11PARP1PDPK1GRM5 | |
| SCHEMBL12056336 | 0.83 | CLK4 (0.49) | PARP10PARP11GRM5 | |
| SCHEMBL18199057 | 0.80 | PARP10 (0.40) | PARP10PARP11PARP1F7F3 | |
| SCHEMBL22797297 | 0.78 | ALDH1A1 (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11807635-B2 | Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-11-07 | — | — | US | disclosed |
| US-20230312556-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230312556-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230250095-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | TUOJIE BIOTECH(SHANGHAI) CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-20230250095-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | TUOJIE BIOTECH(SHANGHAI) CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| WO-2023125944-A1 | COMPOUND CONTAINING HETEROCYCLIC RING | 正大天晴药业集团股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20220144847-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | ELLIPSES PHARMA LTD (GB) | 2022-05-12 | — | — | US | disclosed |
| US-20100004231-A1 | INHIBITORS OF BURTON'S TYROSINE KINASE | ROCHE PALO ALTO LLC | 2010-01-07 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| WO-2009098144-A1 | NOVEL PYRIDINONES AND PYRIDAZINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-13 | — | — | WO | disclosed |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-05 | — | — | US | disclosed |
| US-7453002-B2 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-7453002-B2 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807635-B2 | Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof | DPP4, DPP3, DPP9 | PARP10 3500/4885PARP11 2330/4885PARP1 3568/4885 |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | PARP10 4153/4885PARP11 3314/4885PARP1 4254/4885 |
| US-20230250095-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | P2RX7, P2RX3, P2RX5 | PARP10 2373/4885PARP11 1778/4885PARP1 2532/4885 |
| US-20220144847-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | NOTUM, FURIN, CYP4A11 | PARP10 2736/4885PARP11 1992/4885PARP1 3379/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | PARP10 4688/4885PARP11 3544/4885PARP1 3825/4885 |
| US-20100004231-A1 | INHIBITORS OF BURTON'S TYROSINE KINASE | BTK, LCK, LYN | PARP10 2944/4885PARP11 1770/4885PARP1 3160/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | PARP10 1288/4885PARP11 1482/4885PARP1 2189/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | PARP10 315/4885PARP11 160/4885PARP1 286/4885 |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | PARP10 1341/4885PARP11 992/4885PARP1 2786/4885 |
| US-20230312556-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | AHR, ARNT, NOTUM | PARP10 3077/4885PARP11 2285/4885PARP1 3448/4885 |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | BTK, SYK, LYN | PARP10 1286/4885PARP11 960/4885PARP1 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.